JPMorgan Chase & Co. Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $160.00

Charles River Laboratories International (NYSE:CRL) had its price target cut by JPMorgan Chase & Co. from $165.00 to $160.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Several other analysts also recently weighed in on the company. Barclays dropped their price target on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, February 19th. UBS Group lifted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, December 15th. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average target price of $205.36.

Charles River Laboratories International Trading Up 0.8%

NYSE CRL opened at $180.83 on Monday. Charles River Laboratories International has a 12-month low of $99.80 and a 12-month high of $228.88. The company has a fifty day simple moving average of $168.66 and a two-hundred day simple moving average of $182.61. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The stock has a market cap of $8.92 billion, a P/E ratio of -61.09, a P/E/G ratio of 2.17 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares during the period. Invesco Ltd. lifted its holdings in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the period. State Street Corp boosted its position in Charles River Laboratories International by 2.2% in the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after purchasing an additional 40,535 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Charles River Laboratories International by 27.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after purchasing an additional 311,319 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Charles River Laboratories International by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after purchasing an additional 9,756 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.